financetom
Business
financetom
/
Business
/
Goldman Sachs Raises CEO David Solomon's Compensation to $39 Million in 2024
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Goldman Sachs Raises CEO David Solomon's Compensation to $39 Million in 2024
Jan 17, 2025 7:37 AM

10:23 AM EST, 01/17/2025 (MT Newswires) -- Goldman Sachs Group ( GS ) said in a regulatory filing Friday its board has approved to increase Chief Executive David Solomon's total annual compensation to $39 million in 2024 from $31 million in 2023.

Solomon and Chief Operating Officer John Waldron were also given restricted stock units valued at $80 million each with a five-year vesting period, the Wall Street bank added in its 8-K filing with the US Securities and Exchange Commission.

The compensations were approved because of "strong firmwide financial performance" last year, and a "significant" yearly improvement, Goldman said.

Price: 618.49, Change: +5.50, Percent Change: +0.90

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
US Treasury Dept issues sanctions related to Salt Typhoon hack
US Treasury Dept issues sanctions related to Salt Typhoon hack
Jan 17, 2025
WASHINGTON (Reuters) - The U.S. Treasury department on Friday issued cyber-related sanctions related to the Salt Typhoon hack on Singaporean Yin Kechen and cybersecurity company Sichuan Juxinhe Network Technology Co., according to a statement. ...
Zai Lab's Schizophrenia Drug Application Accepted by Chinese Regulator; Shares Rise
Zai Lab's Schizophrenia Drug Application Accepted by Chinese Regulator; Shares Rise
Jan 17, 2025
10:20 AM EST, 01/17/2025 (MT Newswires) -- Zai Lab ( ZLAB ) said Friday that its new drug application for KarXT to treat adult patients with schizophrenia was accepted by China's National Medical Products Administration. The application is backed by results from a phase 1 China pharmacokinetics study, the phase 3 China study and data from global Emergent clinical programs,...
Bausch Health Notes Xifaxan 550 mg Selected For Medicare 2nd Round Negotiations
Bausch Health Notes Xifaxan 550 mg Selected For Medicare 2nd Round Negotiations
Jan 17, 2025
10:27 AM EST, 01/17/2025 (MT Newswires) -- Bausch Health Companies ( BHC ) , down near 1% at last look, on Friday said the Centers for Medicare and Medicaid Services (CMS) has selected Xifaxan (rifaximin) 550 mg tablets for the second round of negotiation as part of the Inflation Reduction Act. We look forward to engaging in open and transparent...
Goldman Sachs Raises CEO David Solomon's Compensation to $39 Million in 2024
Goldman Sachs Raises CEO David Solomon's Compensation to $39 Million in 2024
Jan 17, 2025
10:23 AM EST, 01/17/2025 (MT Newswires) -- Goldman Sachs Group ( GS ) said in a regulatory filing Friday its board has approved to increase Chief Executive David Solomon's total annual compensation to $39 million in 2024 from $31 million in 2023. Solomon and Chief Operating Officer John Waldron were also given restricted stock units valued at $80 million each...
Copyright 2023-2025 - www.financetom.com All Rights Reserved